Immunogenicity of Seven-Valent Pneumococcal Conjugate Vaccine Administered at 6, 14 and 40 Weeks of Age in South African Infants

Details

• Alternative Title:
  PLoS One
• Personal Author:
  Jones, Stephanie A. ; Groome, Michelle ; Koen, Anthonet ; Van Niekerk, Nadia ; Sewraj, Poonam ; Kuwanda, Locadiah ; Izu, Alane ; Adrian, Peter V. ; Madhi, Shabir A.
• Description:
  Background
  
  The high cost of pneumococcal conjugate vaccine (PCV) and local epidemiological factors contributed to evaluating different PCV dosing-schedules. This study evaluated the immunogenicity of seven-valent PCV (PCV7) administered at 6-weeks; 14-weeks and 9-months of age.
  
  Methods
  
  250 healthy, HIV-unexposed infants were immunized with PCV7 concurrently with other childhood vaccines. Serotype-specific anti-capsular IgG concentrations were measured one-month following the 1st and 2nd PCV-doses, prior to and two-weeks following the 3rd dose. Opsonophagocytic killing assay (OPA) was measured for three serotypes following the 2nd and 3rd PCV7-doses. Immunogenicity of the current schedule was compared to a historical cohort of infants who received PCV7 at 6, 10 and 14 weeks of age.
  
  Results
  
  The proportion of infants with serotype-specific antibody ≥0.35 µg/ml following the 2nd PCV7-dose ranged from 84% for 6B to ≥89% for other serotypes. Robust antibody responses were observed following the 3rd dose. The proportion of children with OPA ≥8 for serotypes 9V, 19F and 23F increased significantly following the 3rd PCV7-dose to 93.6%; 86.0% and 89.7% respectively. The quantitative antibody concentrations following the 2nd PCV7-dose were comparable to that after the 3rd -dose in the 6-10-14 week schedule. Geometric mean concentrations (GMCs) following the 3rd PCV7-dose were higher for all serotypes in this study compared to the historical cohort.
  
  Conclusions
  
  The studied PCV7 dosing schedule induced good immune responses, including higher GMCs following the 3rd-dose at 9-months compared to when given at 14-weeks of age. This may confer longer persistence of antibodies and duration of protection against pneumococcal disease.
  
  
• Subjects:
  Adult Age Factors Antibodies, Bacterial Antibody Formation Female Humans Infant Male Pneumococcal Infections Pneumococcal Vaccines Retrospective Studies Time Factors

  More +
• Source:
  PLoS One. 2013; 8(8).
• Document Type:
  Journal Article
• Place as Subject:
  South Africa
• Volume:
  8
• Issue:
  8
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:9355572a248621517d5945de5ba3e2fff8a6e1ef3da97d076a8a7586635d75fe
• Download URL:
  https://stacks.cdc.gov/view/cdc/21118/cdc_21118_DS1.pdf
• File Type:
  [PDF - 692.11 KB ]